Biomarkers of kidney injury in children with leukemia after anticancer therapy
Автор: Skrylnikova M.A.
Журнал: Международный журнал гуманитарных и естественных наук @intjournal
Статья в выпуске: 7-3 (70), 2022 года.
Бесплатный доступ
The paper deals with the problem of kidney injury in children with leukemia after anticancer therapy. It is stated that cancer incidence has a steady growing trend all over the world, including the children population of Russia. It is reported that a significant proportion of childhood cancer survivors suffer serious late complications, including heart failure, neurotoxicity, nephrotoxicity, growth failure, hormonal disorders, and secondary cancers. Therefore, current research is focused on the problems of early diagnosis even in the "asymptomatic" period of the disease. Special attention is paid to early diagnosis of kidney disorder in children with leukemia who have received anti-cancer treatment. The aim of research was to study the markers of kidney damage after completion of polychemotherapy and radiation therapy. The results obtained demonstrate that in the first two years after completion of anticancer therapy children with acute lymphoblastic leukemia (ALL) had an increased level of urinary kidney damage-1 molecule (KIM-1). It is highlighted that further long-term follow-up studies are necessary to assess the significance of the urinary KIM-1 and cystatin C in the blood serum and their relationship to kidney damage after anticancer treatment in childhood.
Leukemia, children, anticancer therapy, nephrotoxicity, biomarkers, kidney damage, ckd
Короткий адрес: https://sciup.org/170195176
IDR: 170195176 | DOI: 10.24412/2500-1000-2022-7-3-48-52
Список литературы Biomarkers of kidney injury in children with leukemia after anticancer therapy
- Torre L.A., Siegel R.L., Ward E.M., Jemal A. Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomarkers Prev. 2016. 25: 16-27.
- Nada A., Jetton, J.G. Pediatric onco-nephrology: time to spread the word. Pediatr Nephrol 36, 2227-2255 (2021). https://doi.org/10.1007/s00467-020-04800-3
- Porta C., Bamias A., Danesh F.R., D^bska-Slizien A., Gallieni M., Gertz M.A., Kielstein J.T., Tesarova P., Wong G., Cheung M, Wheeler D.C., Winkelmayer W.C., Malyszko J. Conference Participants. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. Kidney Int. 2020 Nov. 98 (5): 1108-1119. doi: 10.1016/j.kint.2020.06.046. PMID: 33126977.
- Национальный проект «Здравоохранение»
- Geenen M.M., Cardous-Ubbink M.C., Kremer L.C.M. et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer // Journal of the American Medical Association. 2007. Vol. 297, №24, pp. 2705-2715,
- Kooijmans E.C., Bokenkamp A., Tjahjadi N.S., Tettero J.M., van Dulmen-den Broeder E., van der Pal H.J., Veening M.A. Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev. 2019 Mar 11. 3 (3): CD008944. doi: 10.1002/14651858.CD008944.pub3. PMID: 30855726. PMCID: PMC6410614.
- Green D.M., Wang M., Krasin M., Srivastava D., Onder S., Jay D.W., Ness K.K., Greene W., Lanctot JQ, Shelton K.C., Zhu L., Mulrooney D.A., Ehrhardt MJ, Davidoff A.M., Robison L.L., Hudson M.M. Kidney Function after Treatment for Childhood Cancer: A Report from the St. Jude Lifetime Cohort Study. J Am Soc Nephrol. 2021 Mar 2. 32 (4): 983-93. doi: 10.1681/ASN.2020060849. Epub ahead of print. PMID: 33653686. PMCID: PMC8017532.
- Онконефрология: поражения почек при использовании противоопухолевых препаратов. Обзор литературы - Часть 1. Нефрология и диализ. 2020. 22(3): 383-395. DOI: 10.28996/2618-9801-2020-3-383-395
- Lupu§oru M., Lupu§oru G., Ailincai I., Fratila G., Andronesi A., Micu E., Banu M., Costea R., Ismail G. Renal replacement therapy in cancer patients with acute kidney injury (Review). Exp Ther Med. 2021 Aug. 22 (2): 864. doi: 10.3892/etm.2021.10296. Epub 2021 Jun 11. PMID: 34178137; PMCID: PMC8220659.
- Mulrooney D.A., Dover D.C., Li S.et al., "Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study," Cancer. 2008. vol. 112, № 9, pp. 2071-2079.
- Kurt B.A., Nolan V.G., Ness K.K., Neglia J.P., Tersak J.M., Hudson M.M., Armstrong G.T., Hutchinson R.J., Leisenring W.M., Oeffinger K.C., Robison L.L., Arora M. Hospitalization rates among survivors of childhood cancer in the Childhood Cancer Survivor Study cohort. Pediatr Blood Cancer. 2012 Jul 15. 59 (1): 126-32. doi: 10.1002/pbc.24017. Epub 2011 Dec 16. PMID: 22180128. PMCID: PMC3359936.
- Greenberg J.H., Kakajiwala A., Parikh C.R., Furth S. Emerging biomarkers of chronic kidney disease in children. Pediatr Nephrol. 2018 Jun. 33(6): 925-933. doi: 10.1007/s00467-017-3701-9. Epub 2017 Jun 17. PMID: 28624980; PMCID: PMC5733707.
- Bardi E., Bobok I., Olah A.V., Olah E., Kappelmayer J., Kiss C. Cystatin C is a suitable marker of glomerular function in children with cancer. Pediatr Nephrol. 2004 Oct. 19 (10): 11457. doi: 10.1007/s00467-004-1548-3. Epub 2004 Jul 16. PMID: 15258844.
- Гревцева Е.А. Маркеры острого повреждения почек у детей с лейкозами: дис. ... канд. мед. наук: 14.01.08 Воронеж, 2017. - 142 с.
- Zubowska M, Wyka K, Fendler W, Mlynarski W, Zalewska-Szewczyk B. Interleukin 18 as a marker of chronic nephropathy in children after anticancer treatment. Dis Markers. 2013;35(6):811-8. doi: 10.1155/2013/369784. Epub 2013 Nov 27. PMID: 24379519. PMCID: PMC3860090.
- Latoch E., Kononczuk K., Taranta-Janusz K., Muszynska-Roslan K., Sawicka M., Wa-silewska A., Krawczuk-Rybak M. Urinary Beta-2-Microglobulin and Late Nephrotoxicity in Childhood Cancer Survivors. J Clin Med. 2021 Nov 13. 10 (22): 5279. doi: 10.3390/jcm10225279. PMID: 34830560. PMCID: PMC8622945.
- Latoch E, Kononczuk K, Muszynska-Roslan K, Taranta-Janusz K, Wasilewska A, Szymczak E, Trochim J, Krawczuk-Rybak M. Urine NGAL and KIM-1-Tubular Injury Biomarkers in Long-Term Survivors of Childhood Solid Tumors: A Cross-Sectional Study. J Clin Med. 2021 Jan 21. 10 (3): 399. doi: 10.3390/jcm10030399. PMID: 33494327. PMCID: PMC7866176.
- Krawczuk-Rybak M, Kuzmicz M, Kozlowska K, Wysocka J, Kitszel A, Luczynski W. Ocena czynnosci nerek po zakonczeniu leczenia ostrej bialaczki limfoblastycznej u dzieci [Renal function in children after treatment of acute lymphoblastic leukaemia (ALL)]. Med Wieku Rozwoj. 2001 Jul-Sep. 5 (3 Suppl 1): 43-54. Polish. PMID: 12004151.
- Kaya Z, Gursel T, Bakkaloglu SA, Kocak U, Atasever T, Oktar SO. Evaluation of renal function in Turkish children receiving BFM-95 therapy for acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2007 Jun. 24 (4): 257-67. doi: 10.1080/08880010701441286. PMID: 17613868.
